Mga Batayang Estadistika
| LEI | 635400ESQQYRIISTLB94 |
| CIK | 888721 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Trinity Biotech plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Susan O’Connor (353)-1-2769800 Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Ireland (September 2, 2025) — Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics |
|
| September 2, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| August 20, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Susan O’Connor Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Regulatory Approval Granted for Commencement Of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation Approval Facilitates Imm |
|
| August 20, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file a |
|
| August 15, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file a |
|
| August 15, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Gary Keating, PhD Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Receives Regulatory Approval to Begin FDA- Cleared PreClara™ Preeclampsia Testing Service New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleare |
|
| August 12, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annu |
|
| August 12, 2025 |
Exhibit 99.2 Sixth Amended and Restated Credit Agreement and Guaranty dated as of August 7, 2025 among Trinity Biotech, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. TRIB Biosensors Inc. as the Borrowers, The Guarantors from Time to Time Party hereto, as |
|
| August 12, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Gary Keating, Ph.D (353)-1-2769800 Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the compan |
|
| August 12, 2025 |
Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES EXC |
|
| August 8, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating, Ph.D (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with |
|
| August 8, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file a |
|
| July 24, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file ann |
|
| July 24, 2025 |
Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating, Ph.D (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market WILSONVILLE, Oregon and DUBLIN, Ireland (July 24, 2025) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human |
|
| July 1, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file ann |
|
| July 1, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc Susan O’Connor (353)-1-2769800 E-mail: [email protected] RedChip Companies Inc David Gentry (1)-407-644-4256 E-mail: [email protected] Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround -Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects |
|
| June 24, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file ann |
|
| June 24, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc Micheal Roche (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation Strategic Offshore Manufacturing Move Exp |
|
| May 16, 2025 |
Exhibit 4.25 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| May 16, 2025 |
First Amendment to Warrant Certificate Exhibit 4.23 Execution Version First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of December 23, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recitals |
|
| May 16, 2025 |
Third Amendment to Warrant Certificate Exhibit 4.14 Execution Version Third Amendment to Warrant Certificate This Third Amendment to Warrant Certificate, dated as of December 23, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recitals |
|
| May 16, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Gillard, Chief Executive Officer of the Compa |
|
| May 16, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| May 16, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Susan O’Connor, Interim Chief Financial Officer of |
|
| May 16, 2025 |
Second Amendment to Warrant Certificate Exhibit 4.13 Execution Version Second Amendment to Warrant Certificate This Second Amendment to Warrant Certificate, dated as of January 30, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recital |
|
| May 16, 2025 |
TRINITY BIOTECH PLC INCENTIVE-BASED COMPENSATION RECOVERY POLICY ADOPTED 1 December, 2023 Exhibit 97.1 TRINITY BIOTECH PLC INCENTIVE-BASED COMPENSATION RECOVERY POLICY ADOPTED 1 December, 2023 1. Policy Purpose. The purpose of this Incentive-Based Compensation Recovery Policy (the “Policy”) is to enable Trinity Biotech plc. (the “Company”) to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended |
|
| May 16, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We have issued our report dated May 15, 2025, with respect to the consolidated financial statements included in the Annual Report of Trinity Biotech plc on Form 20-F for the year ended December 31, 2024. We consent to the incorporation by reference of said report in the following Registration Statements of Trinity Biotech plc: F |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Susan O’Connor, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| May 16, 2025 |
Exhibit 4.24 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, John Gillard, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi |
|
| May 15, 2025 |
Exhibit 99.1 Execution Version Fifth Amended and Restated Credit Agreement and Guaranty dated as of May 14, 2025 among Trinity Biotech, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. TRIB Biosensors Inc. as the Borrowers, The Guarantors from Time to Time P |
|
| May 15, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual |
|
| May 15, 2025 |
Exhibit 99.2 Press Release dated May 15, 2025 Contact: Trinity Biotech plc Susan O’Connor (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update DUBLIN, Ireland (May 15 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| April 4, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| March 31, 2025 |
TRINITY BIOTECH PLC 4,290,000 American Depositary Shares 85,800,000 A Ordinary Shares PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-286020 TRINITY BIOTECH PLC 4,290,000 American Depositary Shares representing 85,800,000 A Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder named in this prospectus or its permitted assigns, of up to 4,290,000 American Depositary Shares (“ADSs”) (each ADS represents 20 A Ordinary Sha |
|
| March 26, 2025 |
TRINITY BIOTECH PLC March 26, 2025 TRINITY BIOTECH PLC March 26, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Daniel Crawford Re: Trinity Biotech plc Registration Statement on Form F-3 File No. 333- 286020 To Mr. Crawford: The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered |
|
| March 21, 2025 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLE1 Form F-3 (Form Type) TRINITY BIOTECH PLC (Exact Name of Registrant as Specified in its Charter) Newly Registered Security Type Security Class Title Fee Calculation Carry Forward Rule Amount to be Registered (2) Proposed maximum offering price per share (3) Proposed maximum aggregate offering price (3) Fee Rate Amount of registration fee Equity A Ordin |
|
| March 21, 2025 |
Exhibit 4.9 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| March 21, 2025 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 21, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation or organization) Not Applicab |
|
| March 21, 2025 |
Exhibit 4.8 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| March 21, 2025 |
Second Amendment to Warrant Certificate Exhibit 4.4 Execution Version Second Amendment to Warrant Certificate This Second Amendment to Warrant Certificate, dated as of January 30, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recitals |
|
| March 21, 2025 |
Third Amendment to Warrant Certificate Exhibit 4.5 Execution Version Third Amendment to Warrant Certificate This Third Amendment to Warrant Certificate, dated as of December 23, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recitals |
|
| March 21, 2025 |
First Amendment to Warrant Certificate Exhibit 4.7 Execution Version First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of December 23, 2024 (this “Amendment”), is entered into by and among TRINITY BIOTECH PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (the “Holder”). Recitals |
|
| March 14, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| March 14, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc Louise Tallon (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Pric |
|
| March 13, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| March 13, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process DUBLIN, Ireland and |
|
| February 28, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| February 28, 2025 |
Exhibit 99.1 Fourth Amended and Restated Credit Agreement and Guaranty dated as of February 27, 2025 among Trinity Biotech, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. TRIB Biosensors Inc. as the Borrowers, The Guarantors from Time to Time Party hereto, |
|
| February 28, 2025 |
Exhibit 99.2 Contact: Trinity Biotech plc Louise Tallon (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology DUBLIN, |
|
| February 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| February 6, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating, Ph.D (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial Trinity Biotech’s patented technology represents a |
|
| February 4, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 29, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 28, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 28, 2025 |
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Gary Keating, Ph.D Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Tr |
|
| December 27, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-280391 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated August 28, 2024 and December 17, 2024 and Prospectus dated June 21, 2024) TRINITY BIOTECH PLC Up to $2,306,000 American Depositary Shares Representing A Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus supplements dated August 28, 20 |
|
| December 27, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| December 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| December 26, 2024 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan DUBLIN, I |
|
| December 26, 2024 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Third Amended and Restated Credit Agreement and Guaranty dated as of December 23, 2024 among Trinity Biotech, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. TRIB Biosensors Inc. as the Borrowers, The Guar |
|
| December 19, 2024 |
JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Class ‘A’ Ordinary Shares, par value U. |
|
| December 19, 2024 |
Amendment Agreement This Amendment Agreement (hereinafter referred to as "this Agreement") is entered into on December 17, 2024 (hereinafter referred to as the “Execution Date”) by and among the following parties: 1. |
|
| December 19, 2024 |
TRIB / Trinity Biotech plc - Depositary Receipt (Common Stock) / MiCo IVD Holdings, LLC - EX-99.14 This Agreement shall be provided in accordance with applicable laws and regulations and internal control standards. |
|
| December 19, 2024 |
Share Purchase Agreement DAYLI TRINITY HOLDINGS, Ltd. Mainstreamholdings, Ltd 2024. 12. 17. Share Purchase Agreement Buyer DAYLI TRINITY HOLDINGS, Ltd. Seller Mainstreamholdings, Ltd 2024. 12. 17. Share Purchase Agreement This Share Purchase Agreement (hereinafter referred to as “this Agreement”) is entered into on December 17, 2024 (hereinafter referred to as the “Effective Date”) by and between the parties below: 1. The Buyer, DAYLI TRINITY HOLDINGS, Ltd. (hereinafter referred to as th |
|
| December 18, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| December 18, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV DUBLIN, Ireland (December |
|
| December 17, 2024 |
TRINITY BIOTECH PLC Up to $1,000,000 American Depositary Shares representing A Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-280391 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated August 28, 2024 And Prospectus dated June 21, 2024) TRINITY BIOTECH PLC Up to $1,000,000 American Depositary Shares representing A Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus supplement dated August 28, 2024 and the accompanying |
|
| December 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| December 5, 2024 |
TRINITY BIOTECH PLC 650,000 American Depositary Shares 13,000,000 A Ordinary Shares PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-283273 TRINITY BIOTECH PLC 650,000 American Depositary Shares representing 13,000,000 A Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder named in this prospectus or its permitted assigns, of up to 650,000 American Depositary Shares (“ADSs”) (each ADS represents 20 A Ordinary Shares |
|
| November 29, 2024 |
Exhibit 4.3 FINANCIAL ADVISORY AGREEMENT October 10, 2024 Trinity Biotech plc Dear Louise Tallon: The purpose of this letter (the “Agreement”) is to confirm the engagement of Craig-Hallum Capital Group LLC (“Advisor”) by Trinity Biotech plc (the “Company”) to render financial advisory services to the Company. 1. Engagement of Consultant. The Company hereby engages Advisor and Advisor hereby agrees |
|
| November 29, 2024 |
As filed with the Securities and Exchange Commission on November 29, 2024 Registration No. 333-283273 As filed with the Securities and Exchange Commission on November 29, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation o |
|
| November 29, 2024 |
TRINITY BIOTECH PLC November 29, 2024 TRINITY BIOTECH PLC November 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Chris Edwards Re: Trinity Biotech plc Registration Statement on Form F-3 File No. 333- 283273 To Mr. Edwards: The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered |
|
| November 15, 2024 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) TRINITY BIOTECH PLC (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (2) Proposed maximum offering price per share (3) Proposed maximum aggregate offering price (3) Fee Rate Amount of registration fee Equity A Ordinary |
|
| November 15, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on November 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation or organization) Not Appli |
|
| November 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| November 15, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Q3 2024 Financial Results Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV busine |
|
| November 14, 2024 |
SC 13D/A 1 d879098dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trinity Biotech plc (Name of Issuer) Class A Ordinary Shares, $0.0109 par value per share (Title of Class of Securities) 896438504** (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, |
|
| November 7, 2024 |
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Press Release dated 07 November, 2024 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Ireland (November 7, 2024) — Trinity Biotech plc (Na |
|
| November 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| October 25, 2024 |
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Trinity Biotech plc Louise Tallon (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture DUBLIN, Ireland (October 25, 2024) |
|
| October 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fi |
|
| October 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fi |
|
| October 25, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc Louise Tallon (353)-1-2769800 Novus Diagnostics Ltd. Keith O’Neill (353)-1-2248831 [email protected] LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Te |
|
| October 7, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Gary Keating, Ph.D. Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology DUBLIN, Ireland (October 7, 2024) - T |
|
| October 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fi |
|
| October 2, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file a |
|
| October 2, 2024 |
mExhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS, LIQUIDITY AND CASH FLOWS Interim Results of Operations Six months ended June 30, 2024 compared to six months ended June 30, 2023 Total revenues for H1, 2024 were US$30.5 million, which compares to US$28.7 million in H1, 2023, an increase of US$1.7 million (6.3%), which is broken down as follows: 2024 H1 2023 H1 Increase/ |
|
| October 2, 2024 |
Exhibit 99.1 TRINITY BIOTECH PLC CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Consolidated Statement of Financial Position F-2 Condensed Consolidated Statement of Operations F-3 Condensed Consolidated Statement of Comprehensive Income F-4 Condensed Consolidated Statement of Changes in Equity F-5 Condensed Consolida |
|
| September 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 25, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Gary Keating, Ph.D. Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market -Metabolomics Diagnostics, a deep-tech machine lear |
|
| September 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 20, 2024 |
TRINITY BIOTECH PLC Up to $1,013,706 American Depositary Shares representing A Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-280391 PROSPECTUS SUPPLEMENT (To Prospectus dated June 21, 2024) TRINITY BIOTECH PLC Up to $1,013,706 American Depositary Shares representing A Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus dated June 21, 2024, as supplemented by the prospectus supplement dated July 12, 2024 and the prospect |
|
| September 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 19, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Micheal Roche Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer DUBLIN, Ireland (September 18, 2024) - Trinity Biotech plc ( |
|
| September 10, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating, Ph.D. (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology DUBLIN, Ireland (September 9, 2024) - Trinity Biote |
|
| September 10, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 5, 2024 |
Exhibit 99.1 Trinity Biotech plc Annual Report 2023 This report has been prepared in accordance with the Companies Act 2014 TABLE OF CONTENTS Page Corporate Information 2 Market, Industry and Other Data 3 Cautionary Statement Regarding Forward-Looking Statements 3 Board of Directors & Executive Officers 4 Business Overview 5 Directors’ Report 9 Statement of Directors’ Responsibilities in respect o |
|
| September 5, 2024 |
Letter from the Board of Trinity Biotech plc Exhibit 99.1 Letter from the Board of Trinity Biotech plc 5 September 2024 Dear Shareholder, Annual General Meeting of Trinity Biotech plc (the “Company”) The board of directors (the “Board”) of the Company encloses notice of an annual general meeting of the Company, to be held at the Company’s registered office at IDA Business Park, Bray, County Wicklow, Ireland, A98 H5C8, on 30 September 2024 at |
|
| September 5, 2024 |
Exhibit 99.3 Form of Proxy For use at the annual general meeting to be held at IDA Business Park, Bray, County Wicklow, Ireland at 10:00 am on September 30, 2024 (the "Annual General Meeting"). I/We (BLOCK LETTERS) of being a member/members of the above Company hereby appoint the chairman of the Annual General Meeting *or as my/our proxy to vote for me/us on my/our behalf at the said meeting of th |
|
| September 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| September 5, 2024 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON 30 SEPTEMBER 2024 AT 10:00 AM Exhibit 99.2 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON 30 SEPTEMBER 2024 AT 10:00 AM Notice is hereby given that an annual general meeting of Trinity Biotech plc (the “Company”) will be held at the Company’s registered office at IDA Business Park, Bray, County Wicklow, Ireland, A98 H5C8, on 30 September 2024 at 10:00am for the following purposes: Ordinary Business 1. To re-app |
|
| September 4, 2024 |
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Louise Tallon Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer DUBLIN, Ireland (September 3, 2024) - Trinity Biotech plc (Nasdaq: TRIB), a commercia |
|
| September 4, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will |
|
| August 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fi |
|
| August 28, 2024 |
TRINITY BIOTECH PLC Up to $1,870,000 American Depositary Shares representing A Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-280391 PROSPECTUS SUPPLEMENT (To Prospectus dated June 21, 2024) TRINITY BIOTECH PLC Up to $1,870,000 American Depositary Shares representing A Ordinary Shares This prospectus supplement, relating to the offer and sale of up to $1,870,000 of American Depositary Shares (“ADSs”) representing our A Ordinary Shares, par value $0.0109 per share (“A |
|
| August 27, 2024 |
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Micheal Roche Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales DUBLIN, Ireland (August 26, 2024) - Trinity Biotech plc (Nasdaq: TRIB |
|
| August 27, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| August 21, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| August 21, 2024 |
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director DUBLIN, Ireland (August 20, 2024) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-sta |
|
| August 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file a |
|
| August 20, 2024 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Simon Dunne Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] Trinity Biotech Announces Q2 2024 Financial Results -Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care |
|
| August 7, 2024 |
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Simon Dunne Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements DUBLIN, Ireland (August 06, 2024) -Trinity Biotech plc (Nasdaq: TRIB), a |
|
| August 7, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Micheal Roche Eric Ribner (353)-1-2769800 (1)-646-751-4363 [email protected] RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 [email protected] Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience -Second Quarter 2024 revenues are expected t |
|
| August 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| August 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| July 12, 2024 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Des Fitzgerald, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances und |
|
| July 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F/A (Amendment No. 1) SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE |
|
| July 12, 2024 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 12, 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55420 Ladies and Gentlemen: Trinity Biotech plc, a public limited company incorporated under the laws of Ireland (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (the “Manager”) as follows: 1. Definitions. T |
|
| July 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| July 12, 2024 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, John Gillard, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| July 12, 2024 |
TRINITY BIOTECH PLC Up to $5,500,000 American Depositary Shares representing A Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-280391 PROSPECTUS SUPPLEMENT (To Prospectus dated June 21, 2024) TRINITY BIOTECH PLC Up to $5,500,000 American Depositary Shares representing A Ordinary Shares We have entered into an At the Market Offering Agreement (the “Sales Agreement”), with Craig-Hallum Capital Group LLC (“Craig-Hallum”) relating to the sale of our American Depositary Sha |
|
| July 11, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, County Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| July 11, 2024 |
Trinity Biotech Announces Appointment of A New CFO Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgerald Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces Appointment of A New CFO DUBLIN, Ireland (July 09, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, includ |
|
| June 28, 2024 |
Registration No. 333-280391 As filed with the Securities and Exchange Commission on June 28, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation or or |
|
| June 28, 2024 |
TRINITY BIOTECH PLC INDENTURE Dated as of ________, 20__ Debt Securities TABLE OF CONTENTS Exhibit 4.4 TRINITY BIOTECH PLC Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definition of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 Deno |
|
| June 26, 2024 |
TRINITY BIOTECH PLC June 26, 2024 TRINITY BIOTECH PLC June 26, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Chris Edwards Re: Trinity Biotech plc Registration Statement on Form F-3 File No. 333-280391 To Mr. Edwards: The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered by t |
|
| June 21, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on June 21, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation or organization) Not Applicabl |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) TRINITY BIOTECH PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity A’ Ordinary shares, par value $0. |
|
| May 28, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annu |
|
| May 28, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgerald Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance -Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by |
|
| May 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annu |
|
| May 16, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Mícheál Roche Eric Ribner (353)-1-276-9800 (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 TrinScreen HIV Sales DUBLIN, Ireland (May 13, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on |
|
| May 7, 2024 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-279017 TRINITY BIOTECH PLC 2,800,000 American Depositary Shares representing 56,000,000 ‘A’ Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder named in this prospectus or its permitted assigns, of up to 2,800,000 American Depositary Shares (“ADSs”) (each ADS represents 20 ‘A’ Ordinary |
|
| May 3, 2024 |
TRINITY BIOTECH PLC May 3, 2024 TRINITY BIOTECH PLC May 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Lauren Hamill Re: Trinity Biotech plc Registration Statement on Form F-3 File No. 333-279017 To Ms. Hamill: The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered by the |
|
| May 1, 2024 |
EX-99.5 2 d791149dex995.htm EX-99.5 Exhibit 5 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. |
|
| May 1, 2024 |
SC 13D/A 1 d791149dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares, $0.0109 par value per share (Title of Class of Securities) 896438504** (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York |
|
| April 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file ann |
|
| April 30, 2024 |
Exhibit 4.11 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| April 30, 2024 |
Exhibit 4.20 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD IN THE |
|
| April 30, 2024 |
Exhibit 4.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACES WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL TRANSITION AGREEMENT (this “Agreement”), dated as of December 20, 2023, among Bayer Healthcare LLC, a Delaware limited liability company (“B |
|
| April 30, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on April 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of incorporation or organization) Not Applicab |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Des Fitzgerald, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, John Gillard, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi |
|
| April 30, 2024 |
Waveform Technologies, Inc. Statement of Assets Acquired and Liabilities Assumed Table of Contents Exhibit 99.1 Waveform Technologies, Inc. Statement of Assets Acquired and Liabilities Assumed Table of Contents Page No. Independent Auditors' Report 1 Statement of Assets Acquired and Liabilities Assumed as of January 30, 2024 2 Notes to Statement of Assets Acquired and Liabilities Assumed 3 - 9 Independent Auditors' Report To the Board of Trinity Biotech Plc Opinion We have audited the accompany |
|
| April 30, 2024 |
TRINITY BIOTECH PLC INCENTIVE-BASED COMPENSATION RECOVERY POLICY ADOPTED 1st December 2023 Exhibit 99.7 TRINITY BIOTECH PLC INCENTIVE-BASED COMPENSATION RECOVERY POLICY ADOPTED 1st December 2023 1. Policy Purpose. The purpose of this Incentive-Based Compensation Recovery Policy (the “Policy”) is to enable Trinity Biotech plc. (the “Company”) to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended |
|
| April 30, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Gillard, Chief Executive Officer of the Compa |
|
| April 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| April 30, 2024 |
INVESTOR SUBORDINATION AGREEMENT Exhibit 4.15 EXECUTION VERSION INVESTOR SUBORDINATION AGREEMENT THIS SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of May 3, 2022, by and among MICO IVD HOLDINGS, LLC, as Subordinated Lender party to the Junior Convertible Note described below (including its successors and assigns in such capacity from time to time, the “Subordinated Lender”) and PERCEPTIVE CREDIT HOLDINGS III, LP, |
|
| April 30, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Des Fitzgerald, Interim Chief Financial Officer of |
|
| April 30, 2024 |
DESCRIPTION OF SHARE CAPITAL AND CONSTITUTION OF TRINITY BIOTECH PLC Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND CONSTITUTION OF TRINITY BIOTECH PLC The following is a summary of certain provisions of the Constitution of Trinity Biotech plc, comprising the Memorandum of Association and the Articles of Association. This summary does not purport to be complete and is qualified in its entirety by reference to the complete text of the Constitution, which is included a |
|
| April 30, 2024 |
Trinity Biotech plc Insider trading policy Exhibit 4.21 Trinity Biotech plc Insider trading policy Introduction This document sets out the insider trading policy adhered to by Trinity Biotech Plc (Trinity Biotech). Trinity Biotech's ADSs are listed on the Nasdaq Global Select Market. As such, Trinity Biotech and trading in its securities are subject to SEC rules and U.S securities laws. Certain of these laws prohibit directors, officers, e |
|
| April 30, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We have issued our report dated April 30, 2024, with respect to the consolidated financial statements included in the Annual Report of Trinity Biotech plc on Form 20-F for the year ended December 31, 2023. We consent to the incorporation by reference of said report in the following Registration Statements of Trinity Biotech plc: |
|
| April 30, 2024 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) TRINITY BIOTECH PLC (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (2) Proposed maximum offering price per share (3) Proposed maximum aggregate offering price (3) Fee Rate Amount of registration fee Equity ‘A’ Ordinar |
|
| April 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| April 5, 2024 |
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates Exhibit 99.1 Contact: Trinity Biotech plc Des Fitzgerald (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates DUBLIN, Ireland (April 4, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes ma |
|
| February 20, 2024 |
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change Exhibit 99.1 Contact: Trinity Biotech plc Des Fitzgerald (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change DUBLIN, Ireland (February 13, 2024)…. Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary |
|
| February 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| February 20, 2024 |
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change Exhibit 99.1 Contact: Trinity Biotech plc Des Fitzgerald (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change DUBLIN, Ireland (February 15, 2024)…. Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change |
|
| February 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| February 15, 2024 |
Rule 424(b)(3) File No. 333-111946 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from one share to twenty shares, effective February 23, 2024. Exhibit A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents twenty deposited Shares) THE BANK OF NEW YORK AMERICAN DEPOSITARY RECEIPT F |
|
| February 9, 2024 |
SC 13D 1 d763623dsc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares, $0.0109 par value per share (Title of Class of Securities) 896438306** (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 ( |
|
| February 9, 2024 |
EX-99.1 2 d763623dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. |
|
| February 1, 2024 |
Exhibit 99.2 Press Release dated January 31, 2024 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgearld Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail [email protected] Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India DUBLIN, Ireland, January 31, 2024 (GLOBE NEWSWIRE) - |
|
| February 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| February 1, 2024 |
Exhibit 99.1 Contact: Trinity Biotech plc Des Fitzgerald (353)-1-2769800 LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces Q3 2023 Financial Results & Business Update -Investor call to be held today at 8:30 am EST DUBLIN, Ireland (January 31, 2024) (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) today announced the Compa |
|
| February 1, 2024 |
Exhibit 99.1 Press Release dated January 31, 2024 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgearld Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail [email protected] Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc. -Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company |
|
| February 1, 2024 |
Exhibit 4.21 Execution Version Second Amended and Restated Credit Agreement and Guaranty dated as of January 30, 2024 among Trinity Biotech, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. TRIB Biosensors Inc. as the Borrowers, The Guarantors from Time to T |
|
| February 1, 2024 |
BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 4.20 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Execution copy ASSET AND SHARE PURCHASE AGREEMENT dated as of January 30, 2024 among TRIB BIOSENSORS INC. (as buyer) WAVEFORM TECHNOLOGIES, INC. (as seller) WAVEFORM HOLDINGS, LLC (as seller and parent of sell |
|
| February 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 2, 2024 |
EX-99.10 2 d683070dex9910.htm ENGLISH TRANSLATION OF LOAN AGREEMENT Exhibit 10 This Agreement shall be provided in accordance with applicable laws and regulations and internal control standards. Loan Agreement - Lender - Institutions specified in Appendix 1 - Borrower - Mainstream Holdings, Ltd. December 20, 2023 Table of contents Chapter 1 General Provisions 3 Article 1-1 (Definitions) 3 Article |
|
| January 2, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 2, 2024 |
EX-99.11 3 d683070dex9911.htm ENGLISH TRANSLATION OF PRICE RETURN SWAP AGREEMENT Exhibit 11 Price Return Swap Agreement The Parties hereby enter into the Price Return Swap Agreement (hereinafter referred to as “this Agreement”) on December 20, 2023, as follows: MiCo Ltd. (the “MiCo”) 53, Mosan-ro, Daedeok-myeon, Anseong-si, Gyeonggi-do, Republic of Korea Mainstream Holdings, Ltd. (the “Mainstream” |
|
| January 2, 2024 |
SC 13D/A 1 d620462dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares (Title of Class of Securities) 896438306 (CUSIP Number) Seonkyu Jeon Director and Chairman MiCo Co., Ltd. 68, 68, Dongtansandan 2-gil Hwaseong-si Gyeong |
|
| January 2, 2024 |
REVOCATION OF JOINT FILING AGREEMENT EX-99.7 3 d620462dex997.htm EX-99.7 Exhibit 7 REVOCATION OF JOINT FILING AGREEMENT January 2, 2024 The undersigned is a party to that certain Joint Filing Agreement, dated December 7, 2022 (the “Joint Filing Agreement”). The undersigned hereby revokes the Joint Filing Agreement effective immediately. MiCo Co., Ltd. By: /s/ Suk Yoon Lee Name: Suk Yoon Lee Title: CEO |
|
| January 2, 2024 |
Exhibit 99.1 Press Release dated December 27, 2023 Contact: Trinity Biotech plc LifeSci Advisors, LLC Mícheál Roche Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: [email protected] Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya DUBLIN, Ireland (December 27, 2023)…. Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), |
|
| January 2, 2024 |
EX-99.12 4 d683070dex9912.htm JOINT FILING AGREEMENT Exhibit 12 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Class ‘A’ Ordinary Shares, par value U.S.0.0109 per shar |
|
| January 2, 2024 |
EX-99.6 2 d620462dex996.htm EX-99.6 Exhibit 6 English translation for informational purposes only. Share Purchase Agreement Buyer Mainstream Holdings Co., Ltd. Seller MiCo Co., Ltd. MiCoBioMed Co., Ltd. 2023. 12. 20. Share Purchase Agreement “This Share Purchase Agreement (hereinafter referred to as the ‘Agreement’) is entered into on December 20, 2023 (hereinafter referred to as the ‘Agreement Da |
|
| January 2, 2024 |
SC 13D/A 1 d683070dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares (Title of Class of Securities) 896438306 (CUSIP Number) Park Heejoo President and CEO MiCo IVD Holdings, LLC 85 Orchard Road Skillman, New Jersey 08558 |
|
| December 19, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| December 19, 2023 |
Exhibit 99.1 Press Release dated December 18, 2023 Contact: Trinity Biotech plc Eric Ribner Des Fitzgerald LifeSci Advisors, LLC +353-1-2769800 +1-646 -751-4363 E-mail: [email protected] Trinity Biotech Announces Management Changes John Gillard Named Chief Executive Officer Des Fitzgerald Named Interim Chief Financial Officer DUBLIN, Ireland (December 18, 2023)…. Trinity Biotech |
|
| November 29, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| November 29, 2023 |
Exhibit 99.1 Contact: Trinity Biotech plc Eric Ribner John Gillard LifeSci Advisors, LLC +353-1-2769800 +1-646 -751-4363 E-mail: [email protected] Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares DUBLIN, Ireland, November 28, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “ |
|
| October 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| October 6, 2023 |
Trinity Biotech Announces Q2 2023 Financial Results Exhibit 99.1 Contact: Trinity Biotech plc John Gillard (353)-1-2769800 Lytham Partners, LLC Joe Diaz (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Q2 2023 Financial Results DUBLIN, Ireland (October 3, 2023)... Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory market |
|
| October 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| September 12, 2023 |
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Press Release dated September 11, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail [email protected] Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement DUBLIN, Ireland, September 11, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) |
|
| September 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| September 6, 2023 |
Exhibit 99.1 Trinity Biotech plc Annual Report 2022 This report has been prepared in accordance with the Irish Companies Act 2014 TABLE OF CONTENTS Page Corporate Information 1 Market, Industry and Other Data 2 Cautionary Statement Regarding Forward-Looking Statements 2 Board of Directors & Executive Officers 3 Business Overview 4 Directors’ Report 7 Statement of Directors’ Responsibilities in res |
|
| September 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| September 5, 2023 |
Exhibit 99.3 Form of Proxy For use at the annual general meeting to be held at IDA Business Park, Bray, County Wicklow, Ireland at 10:00 am on September 29, 2023 (the "Annual General Meeting"). I/We (BLOCK LETTERS) of being a member/members of the above Company hereby appoint the chairman of the Annual General Meeting *or as my/our proxy to vote for me/us on my/our behalf at the said meeting of th |
|
| September 5, 2023 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 29, 2023 AT 10:00 AM Exhibit 99.2 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 29, 2023 AT 10:00 AM Notice is hereby given that an annual general meeting of Trinity Biotech plc (the "Company") will be held at the Company’s registered office at IDA Business Park, Bray, County Wicklow, Ireland, A98 H5C8, on September 29, 2023 at 10:00am for the following purposes: Ordinary Business 1. To re-a |
|
| September 5, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will fil |
|
| September 5, 2023 |
Letter from the Board of Trinity Biotech plc Exhibit 99.1 Letter from the Board of Trinity Biotech plc September 4, 2023 Dear Shareholder, Annual General Meeting of Trinity Biotech plc (the “Company”) The board of directors (the "Board") of the Company encloses notice of an annual general meeting of the Company, to be held at the Company’s registered office at IDA Business Park, Bray, County Wicklow, Ireland, A98 H5C8, on September 29, 2023 |
|
| July 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file ann |
|
| July 10, 2023 |
Trinity Biotech Announces Q1 2023 Financial Results Exhibit 99.1 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Q1 2023 Financial Results DUBLIN, Ireland (July 6, 2023)... Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, |
|
| May 16, 2023 |
DESCRIPTION OF SHARE CAPITAL AND CONSTITUTION OF TRINITY BIOTECH PLC Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND CONSTITUTION OF TRINITY BIOTECH PLC The following is a summary of certain provisions of the Constitution of Trinity Biotech plc, comprising the Memorandum of Association and the Articles of Association. This summary does not purport to be complete and is qualified in its entirety by reference to the complete text of the Constitution, which is included a |
|
| May 16, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| May 16, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We have issued our report dated May 16, 2023, with respect to the consolidated financial statements included in the Annual Report of Trinity Biotech plc on Form 20-F for the year ended December 31, 2022. We consent to the incorporation by reference of said report in the following Registration Statements of Trinity Biotech plc: F |
|
| May 16, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Gillard, Chief Financial Officer of the Compa |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Aris Kekedjian, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| May 16, 2023 |
Exhibit 1.1 COMPANY NUMBER 183476 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF TRINITY BIOTECH PUBLIC LIMITED COMPANY COMPANY NUMBER 183476 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF TRINITY BIOTECH PUBLIC LIMITED COMPANY As altered by a special resolution dated 30 September 2022 1 The name of the Company is Trinity Biotech Public Li |
|
| May 16, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trinity Biotech plc (the “Company”) on Form 20-F for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronan O’Caoimh, Chief Executive Officer of the Com |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, John Gillard, certify that: 1. I have reviewed this annual report on Form 20-F of Trinity Biotech plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi |
|
| May 16, 2023 |
This Employment Agreement (this Exhibit 4.17 This Employment Agreement (this "Agreement") is entered into as of October 3, 2022 between Aris Kekedjian ("Employee") and Trinity Biotech, Inc. ("Trinity" or the "Company"). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement. NOW, THEREFORE, in consideration of the mutual promises made herein, intending to be legally bound, the par |
|
| May 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annu |
|
| May 8, 2023 |
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule Exhibit 99.1 Press Release dated May 5, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule DUBLIN, Ireland, May 5, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and man |
|
| May 1, 2023 |
Exhibit 99.1 Contact: Trinity Biotech plc John Gillard (353)-1-2769800 Lytham Partners, LLC Joe Diaz (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth DUBLIN, Ireland, April 27, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading de |
|
| May 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| April 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| April 25, 2023 |
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Press Release dated April 24, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement DUBLIN, Ireland, April 24, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a lea |
|
| April 24, 2023 |
Exhibit 4.10.1 First Amendment to Amended and Restated Credit Agreement and Guaranty This First Amendment to Amended and Restated Credit Agreement and Guaranty, dated as of April 20, 2023 (this “First Amendment”), is entered into by and among TRINITY BIOTECH, INC., a Delaware corporation (“U.S. Holdings”), FITZGERALD INDUSTRIES INTERNATIONAL, INC., a Delaware corporation (“U.S. Fitzgerald”), CLARK |
|
| April 24, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annua |
|
| April 24, 2023 |
BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 4.15 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Execution Version DATED APRIL 20, 2023 TRINITY BIOTECH PLC -and- TRINITY BIOTECH MANUFACTURING LIMITED -and- TRINITY BIOTECH, INC. -and- AALTO BIO HOLDING LIMITED -and- BIOSYNTH INTERNATIONAL INC -and- GALLUS |
|
| April 24, 2023 |
Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth Exhibit 99.1 Contact: Trinity Biotech plc John Gillard (353)-1-2769800 Lytham Partners, LLC Joe Diaz (1)-602-889-9700 E-mail [email protected] Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) - Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of |
|
| March 31, 2023 |
TRINITY BIOTECH PLC 2,500,000 American Depositary Shares 10,000,000 ‘A’ Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-264992 PROSPECTUS TRINITY BIOTECH PLC 2,500,000 American Depositary Shares representing 10,000,000 ‘A’ Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholder named in this prospectus or its permitted assigns, of up to 2,500,000 American Depositary Shares (“ADSs”) (each ADS represents 4 ‘A’ Ordinary |
|
| March 27, 2023 |
Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm Exhibit 99.1 Press Release dated March 22, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC Mícheál Roche Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm DUBLIN, Ireland (March 22, 2023)…. Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer an |
|
| March 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| March 27, 2023 |
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 Press Release dated March 23, 2023 Contact: Trinity Biotech plc John Gillard (353)-1-2769800 Lytham Partners, LLC Joe Diaz (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results DUBLIN, Ireland (March 23, 2023)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic |
|
| March 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file an |
|
| March 23, 2023 |
Registration No. 333-264992 As filed with the Securities and Exchange Commission on March 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) Republic of Ireland (State or other jurisdiction of inc |
|
| February 22, 2023 |
First Amendment to Warrant Certificate Exhibit 4.12.1 First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of February 21, 2023 (this “Amendment”), is entered into by and among Trinity Biotech PLC, a public limited company organized and existing under the laws of Ireland (the “Company”) and Perceptive Credit Holdings III, LP, a Delaware limited partnership (the “Holder”). Recitals Whereas, the Co |
|
| February 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| February 22, 2023 |
Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions Exhibit 99.1 Press Release dated February 22, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions DUBLIN, Ireland (February 22, 2023)…. Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading deve |
|
| February 22, 2023 |
Exhibit 4.10 Amended and Restated Credit Agreement and Guaranty dated as of February 21, 2023 among Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution), Primus Corporation, MarDx Diagnostics, Inc. and IMMCO Diagnostics, Inc. as the Borrowers, The Guarantors from Time to Tim |
|
| February 13, 2023 |
TRIB / Trinity Biotech PLC / STONEHILL CAPITAL MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A 1 d456878dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares represented by American Depositary Shares (Title of Class of Securities) 896438306** (CUSIP Number) December 31, 2022 (Date of Event which Requires Fi |
|
| January 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| January 10, 2023 |
Exhibit 99.1 Press Release date January 9, 2023 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry DUBLIN, Ireland (January 9, 2023)…. Trinity Biotech (Nasdaq: T |
|
| December 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| December 16, 2022 |
Trinity Biotech Announces Q3 2022 Financial Results Exhibit 99.1 Press Release dated December 15, 2022 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Q3 2022 Financial Results DUBLIN, Ireland (December 15, 2022)... Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the poin |
|
| December 9, 2022 |
Exhibit 99.1 Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN DUBLIN – December 9, 2022 – Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal |
|
| December 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 6-K 1 zk2228873.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the regis |
|
| December 8, 2022 |
TRIB / Trinity Biotech PLC / MiCo IVD Holdings, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Trinity Biotech plc (Name of Issuer) Class ‘A’ Ordinary Shares (Title of Class of Securities) 896438306** (CUSIP Number) Seonkyu Jeon Manager, President and CEO MiCo IVD Holdings, LLC 85 Orchard Road Skillman, New Jersey 08558 512-650-6322 With a copy to: |
|
| December 8, 2022 |
Member’s Requisition for Extraordinary General Meeting EXHIBIT 5 21.10.2022 Member’s Requisition for Extraordinary General Meeting MiCo IVD Holdings, LLC 5 Orchard Rd Skillman NJ 08558 The Directors Trinity Biotech PLC IDA Business Park Bray Co. Wicklow CRO No. 183476 BY HAND AND BY REGISTERED POST 21 October 2022 Trinity Biotech Public Limited Company (the “Company”) and Sections 146 and 178 of the Companies Act 2014 Dear Sirs As you are aware, we ar |
|
| December 8, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Class ‘A’ Ordinary Shares, par value U. |
|
| November 15, 2022 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS, LIQUIDITY AND CASH FLOWS Interim Results of Operations Six months ended June 30, 2022 compared to six months ended June 30, 2021 Total revenues for H1, 2022 were US$37.2 million, which compares to US$51.4 million in H1, 2021, a decrease of US$14.2 million and which were broken down as follows: 2022 H1 2021 H1 Increase / (d |
|
| November 15, 2022 |
Exhibit 99.1 TRINITY BIOTECH PLC CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2022 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Consolidated Statement of Financial Position F-2 Condensed Consolidated Statement of Operations F-3 Condensed Consolidated Statement of Comprehensive Income F-4 Condensed Consolidated Statement of Changes in Equity F-5 Condensed Consolida |
|
| November 15, 2022 |
Second Amendment to Credit Agreement and Guaranty Exhibit 99.3 Execution Version Second Amendment to Credit Agreement and Guaranty This Second Amendment to Credit Agreement and Guaranty, dated as of October 28, 2022 (this ?Second Amendment?), is entered into by and among Trinity Biotech, Inc., a Delaware corporation (?U.S. Holdings?), Fitzgerald Industries International, Inc., a Delaware corporation (?U.S. Fitzgerald?), Clark Laboratories, Inc. ( |
|
| November 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| November 4, 2022 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2228655.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the regis |
|
| November 4, 2022 |
Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance Exhibit 99.1 Press Release dated November 3, 2022 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance DUBLIN, Ireland (November 3, 2022)?. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and man |
|
| November 4, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| November 2, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file |
|
| November 2, 2022 |
Exhibit 99.1 Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN DUBLIN ?November 1, 2022 ? Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal |
|
| October 27, 2022 |
Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors Exhibit 99.1 Press Release dated October 26, 2022 Contact: Trinity Biotech plc John Gillard (353)-1-2769800 Lytham Partners, LLC Joe Diaz (1)-602-889-9700 E-mail: [email protected] Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors DUBLIN, Ireland (October 26, 2022) …. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of dia |
|
| October 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2228609.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F O R M 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the regist |
